Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Posterior Urethral Cancer, Recurrent Bladder Cancer, Recurrent Urethral Cancer, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Ureter Cancer, Urethral Cancer Associated With Invasive Bladder Cancer
Conditions
Brief summary
This study is about two chemotherapy study drug combinations (regimens) that are used for urothelial (bladder or upper urinary tract) cancer. Both study drug regimens, gemcitabine (gemcitabine hydrochloride) plus cisplatin, and high-dose-intensity MVAC (methotrexate, vinblastine, doxorubicin plus cisplatin), are standard chemotherapy regimens. Both regimens are used to treat people with urothelial cancer that has spread to other organs. Both study drug regimens have been proven to be effective in lowering the risk of the cancer coming back, but it is not known which regimen is the best. This study hopes to learn whether there is a difference in the effectiveness and side effects of these two study drug regimens when they are given to people who have had their urothelial cancer completely removed.
Detailed description
PRIMARY OBJECTIVES To estimate the difference in the rate of unacceptable toxicity for dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) and gemcitabine and cisplatin (GC) in the adjuvant treatment of urothelial cancer. SECONDARY OBJECTIVES To compare rates of disease recurrence at 3 years between dose-dense MVAC and GC. To determine whether molecular markers excision repair cross-complementing-1 (ERCC-1) ribonucleoside-diphosphate reductase M-1 (RRM-1), breast cancer 1 (BRCA1) topoisomerase 2-alpha (Top2A) and protein 53 (p53) can predict those patients more likely to benefit from chemotherapy. To investigate the potential utility of cytidine deaminase (CDA), ERCC-1, xeroderma pigmentosum group D (XPD), glutathione S-transferase P-1 (GSTP-1) and glutathione S-transferase M-1 (GSTM-1) as molecular markers which predict occurrence of significant toxicity during adjuvant chemotherapy for urothelial cancer. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM A: Patients receive cisplatin intravenously (IV) on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive methotrexate IV on day 1, vinblastine IV, doxorubicin hydrochloride IV, cisplatin IV on day 2 and pegfilgrastim subcutaneously (SC) on day 3. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 3 years.
Interventions
DRUGcisplatin
Given IV
DRUGgemcitabine hydrochloride
Given IV
DRUGmethotrexate
Given IV
DRUGvinblastine
Given IV
DRUGdoxorubicin hydrochloride
Given IV
BIOLOGICALpegfilgrastim
Given SC
OTHERlaboratory biomarker analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
University of Southern California
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed high-grade urothelial carcinoma, stage T3bN0, T4N0 or any T stage with lymph node involvement, completely resected; including upper tract urothelial carcinoma * The dominant histology must be transitional cell or urothelial but foci of other histologies less than 20 percent of the total tumor volume are permitted * Absence of metastatic disease on radiographic imaging * Patients must be enrolled and able to start treatment within 90 days of radical cystectomy or radical nephrectomy * Creatinine less than institutional upper limit of normal (ULN) or clearance greater or equal to 50 mL/min (may be calculated by Cockcroft-Gault formula or measured from 24-hour urine collection) * Serum total bilirubin less or equal to 1.5 x ULN (except for patients with Gilbert's) * Alkaline phosphatase less or equal to 2.5 x ULN * Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvate transaminase (SGPT) less or equal to 2.5 x ULN * White blood cells (WBC) greater or equal to 3000 * Absolute neutrophil count (ANC) greater or equal to 1500 * Hemoglobin (Hb) greater or equal to 9 * Platelets greater or equal to 100,000 * Normal left ventricular ejection fraction, by echocardiogram or multi gated acquisition scan (MUGA) * Patients must be recovered from surgery * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Willing and able to provide informed consent * Willingness to use barrier contraception during study period
Exclusion criteria
* The presence of significant pleural effusion or ascites * Prior systemic chemotherapy for urothelial carcinoma including neoadjuvant chemotherapy (prior intravesical therapy is permitted) * History of malignancy within preceding 5 years, aside from non-melanoma skin cancer or previously treated or incidentally detected prostate cancer with undetectable PSA (after radical cystectomy or prostate cancer therapy) * Peripheral neuropathy greater than grade 1 * The presence of active heart disease such as congestive heart failure or unstable angina
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of unacceptable toxicity graded according to Common Terminology Criteria (CTC) v4.0 | Assessed up to 3 years | 80% confidence intervals (CI) will be constructed; for unacceptable toxicity, the confidence interval will be one-sided. |
Secondary
| Measure | Time frame |
|---|---|
| Disease-free survival | From radical cystectomy to the time cancer recurrence is detected by clinical findings or during surveillance imaging, at 3 years |
Outcome results
None listed